生長激素缺乏症市場規模、佔有率和成長分析（按類型、診斷、治療方法、給藥途徑、最終用戶和地區分類）—2026-2033年產業預測

預計到 2024 年，生長激素缺乏症市場規模將達到 39 億美元，到 2025 年將成長至 41.2 億美元，到 2033 年將成長至 63.2 億美元，在預測期（2026-2033 年）內複合年成長率為 5.5%。

由於腦損傷、遺傳疾病和先天性異常等因素，生長激素缺乏症 (GHD) 的發生率不斷上升，推動了對生長激素荷爾蒙療法的需求。在英國，大約每 3500 至 4000 名兒童中就有 1 名患有兒童GHD，促進了該行業的擴張。這一成長趨勢推動了旨在開發創新治療方法的研發活動。該領域的最新進展展現了行業的強勁勢頭，新治療方法獲​​得上市核准的顯著成功也體現了致力於滿足患者需求的決心。隨著人們對 GHD 的認知不斷提高以及治療方案的不斷改進，荷爾蒙療法市場預計將顯著成長，並被視為投資和創新的關鍵領域。

生長激素缺乏症市場成長要素

全球生長激素缺乏症市場的主要促進因素之一是醫療專業人員和大眾對生長激素缺乏症 (GHD) 的認知和盛行率不斷提高。隨著教育活動和研究不斷揭示 GHD 的症狀和長期影響，越來越多的人開始尋求診斷和治療方案。醫療技術和診斷工具的進步進一步增強了這種認知，使得 GHD 病例的識別更加精準。此外，荷爾蒙療法作為一種有效的治療選擇，其日益普及也推動了對荷爾蒙療法的需求，從而促進了市場成長。

生長激素缺乏症市場限制

全球生長激素缺乏症市場的主要限制因素之一是生長激素荷爾蒙療法的高成本。治療相關費用，包括合成荷爾蒙的價格、監測和持續諮詢等，對許多患者和醫療系統而言都難以負擔。這種經濟負擔會限制患者獲得必要治療的機會，尤其是在中低收入國家，並阻礙整體市場成長。此外，保險覆蓋範圍的差異和缺乏統一的治療指南也構成了進一步的障礙，可能妨礙及時干預，並增加未治療的生長激素缺乏症病例數。

生長激素缺乏症市場趨勢

生長激素缺乏症市場正經歷著變革性的轉變，這主要得益於藥物傳遞系統的技術進步。穿戴式貼片、無針裝置和自動注射器等創新技術正在提升生長激素荷爾蒙療法的便利性和患者依從性。長效製劑和植入式裝置的出現，實現了藥物的緩釋性釋放和給藥，從而減少了給藥頻率，並提高了患者滿意度。這種改變不僅改善了治療效果，也使更多不同背景的患者能夠獲得治療。藥物輸送系統的持續發展，為專注於生長激素缺乏症的製藥產業創造了巨大的成長和擴張機會。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管分析

全球生長激素缺乏症市場規模（按類型和複合年成長率分類）（2026-2033 年）

• 兒童生長激素缺乏症
• 成人生長激素缺乏症

全球生長激素缺乏症市場規模（按診斷和複合年成長率分類）（2026-2033 年）

• 血液檢查
• 影像檢查
• 電腦斷層掃描（CT）
• 磁振造影（MRI）
• 其他

全球生長激素缺乏症市場規模（依治療方法分類）及複合年成長率（2026-2033 年）

• 藥物治療
• 重組人體生長荷爾蒙
• 人類腦下垂體萃取物
• 外科手術

全球生長激素缺乏症市場規模（依給藥途徑及複合年成長率分類）（2026-2033 年）

• 靜脈注射
• 肌肉內注射
• 其他

全球生長激素缺乏症市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院
• 居家醫療
• 專科診所
• 其他

全球生長激素缺乏症市場規模（按分銷管道和複合年成長率分類）（2026-2033 年）

• 醫院藥房
• 網路藥房
• 零售藥房

全球生長激素缺乏症市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Pfizer Inc.（USA）
• Eli Lilly and Company（USA）
• Novo Nordisk A/S（Denmark）
• Ipsen SA（France）
• Ascendis Pharma A/S（Denmark）
• Ferring Pharmaceuticals（Switzerland）
• OPKO Health Inc.（USA）
• Genexine, Inc.（South Korea）
• LG Chem Ltd.（South Korea）
• Anhui Anke Biotechnology（China）
• Teva Pharmaceutical Industries Ltd.（Israel）
• JCR Pharmaceuticals Co., Ltd.（Japan）
• Shanghai United Cell Biotechnology Co., Ltd.（China）
• Hanmi Pharmaceutical Co., Ltd.（South Korea）
• Strongbridge Biopharma plc（USA）
• GeneScience Pharmaceuticals Co., Ltd.（China）
• Cipla Limited（India）
• BIOCAD（Russia）
• Krka, dd（Slovenia）
• OPBIO Factory Co., Ltd.（South Korea）

結論與建議

Growth Hormone Deficiency Market size was valued at USD 3.9 Billion in 2024 and is poised to grow from USD 4.12 Billion in 2025 to USD 6.32 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).

The rising incidence of growth hormone deficiency (GHD), driven by factors such as brain injuries, genetic disorders, and congenital abnormalities, is increasing the demand for growth hormone therapies. In the UK, pediatric GHD affects approximately 1 in every 3,500 to 4,000 children, contributing to the industry's expansion. This growing prevalence is prompting intensified research and development efforts aimed at innovative treatments. Recent advancements in the field underscore the industry's momentum, with notable achievements in securing marketing authorizations for new therapies, reflecting a commitment to addressing the needs of affected populations. As awareness of GHD expands and treatment options evolve, the market for growth hormone therapies is poised for significant growth, highlighting a critical area for investment and innovation.

Top-down and bottom-up approaches were used to estimate and validate the size of the Growth Hormone Deficiency market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Growth Hormone Deficiency Market Segments Analysis

Global Growth Hormone Deficiency Market is segmented by Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel and region. Based on Type, the market is segmented into Pediatric Growth Hormone Deficiency and Adult Growth Hormone Deficiency. Based on Diagnosis, the market is segmented intoBlood Tests, Imaging Tests, Computerized tomography (CT) scans, Magnetic resonance imaging (MRI) and Others. Based on Treatment, the market is segmented into Pharmacological Therapy, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts, and Surgery. Based on Route of Administration, the market is segmented into Intravenous, Intramuscular and Others. Based on End User, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Growth Hormone Deficiency Market

One key market driver for the global growth hormone deficiency market is the increasing awareness and prevalence of growth hormone deficiency (GHD) among both healthcare professionals and the general public. As educational initiatives and research highlight the symptoms and long-term impacts of GHD, more individuals are seeking diagnosis and treatment options. This rising awareness is compounded by advancements in medical technology and diagnostic tools, leading to better identification of GHD cases. Furthermore, the acceptance of hormone therapy as a viable treatment option has resulted in a growing demand for growth hormone therapies, thereby propelling market growth.

Restraints in the Growth Hormone Deficiency Market

One of the key market restraints for the global growth hormone deficiency market is the high cost associated with growth hormone therapy. The expenses related to treatment, including the price of synthetic hormones, monitoring, and ongoing medical consultations, can be prohibitive for many patients and healthcare systems. This financial burden may limit access to necessary therapies, particularly in low- and middle-income countries, hindering overall market growth. Additionally, insurance coverage discrepancies and the lack of universal guidelines for treatment can create further barriers, preventing timely intervention and leading to unaddressed cases of growth hormone deficiency.

Market Trends of the Growth Hormone Deficiency Market

The Growth Hormone Deficiency market is experiencing a transformative shift driven by technological advancements in drug delivery systems. Innovations such as wearable patches, needle-free devices, and autoinjectors are enhancing the convenience and adherence to growth hormone therapies. The rise of long-acting formulations and implantable devices allows for extended-release and sustained delivery, minimizing the frequency of dosing and improving patient satisfaction. This evolution not only leads to better treatment outcomes but also boosts accessibility for diverse patient populations. As the landscape of drug delivery continues to evolve, it creates significant opportunities for growth and expansion within the pharmaceutical industry focused on Growth Hormone Deficiency.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis

Global Growth Hormone Deficiency Market Size by Type & CAGR (2026-2033)

• Market Overview
• Pediatric Growth Hormone Deficiency
• Adult Growth Hormone Deficiency

Global Growth Hormone Deficiency Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Blood Tests
• Imaging Tests
• Computerized tomography (CT) scans
• Magnetic resonance imaging (MRI)
• Others

Global Growth Hormone Deficiency Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Pharmacological Therapy
• Recombinant Human Growth Hormone
• Human Pituitary Gland Extracts
• Surgery

Global Growth Hormone Deficiency Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Intravenous
• Intramuscular
• Others

Global Growth Hormone Deficiency Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Growth Hormone Deficiency Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Growth Hormone Deficiency Market Size & CAGR (2026-2033)

• North America (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
  • US
  • Canada
• Europe (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Diagnosis, Treatment, Route of Administration, End User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ascendis Pharma A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OPKO Health Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genexine, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LG Chem Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anhui Anke Biotechnology (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• JCR Pharmaceuticals Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai United Cell Biotechnology Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hanmi Pharmaceutical Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Strongbridge Biopharma plc (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeneScience Pharmaceuticals Co., Ltd. (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BIOCAD (Russia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Krka, d. d. (Slovenia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OPBIO Factory Co., Ltd. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations